How Cagrilintide works
Cagrilintide mimics amylin, the co-secreted partner of insulin, acting on the area postrema to signal fullness and slow gastric emptying. Because the pathway sits outside the incretin system, it stacks cleanly with GLP-1 agonists rather than competing with them.
Reported benefits
- Longer-lasting meal satiety
- Complementary to GLP-1 based protocols
- Slower gastric emptying with steadier glucose
- Weekly dosing profile
Reported side effects
Effects reported in published trials, case reports or post-market surveillance. Individual response varies; this list is educational and not exhaustive.
- Nausea and early satiety
- Constipation and bloating
- Injection-site reactions
- Fatigue in the first weeks of titration
Regulatory status & sources
In clinical trials
Not FDA approved. Studied alone and as CagriSema (with semaglutide) in the REDEFINE phase 3 programme.
Safety note
Cagrilintide is presented here for research and educational purposes only. It is not offered for human consumption and nothing on this page is medical advice or a dosing protocol. Read the full safety and disclaimer page.